KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Revenue (2016 - 2025)

Jazz Pharmaceuticals has reported Revenue over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • Quarterly results put Revenue at $1.2 billion for Q4 2025, up 10.09% from a year ago — trailing twelve months through Dec 2025 was $3.4 billion (down 17.18% YoY), and the annual figure for FY2025 was $4.3 billion, up 4.88%.
  • Revenue for Q4 2025 was $1.2 billion at Jazz Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Revenue for JAZZ hit a ceiling of $1.2 billion in Q4 2025 and a floor of $607.6 million in Q1 2021.
  • Median Revenue over the past 5 years was $957.3 million (2023), compared with a mean of $948.8 million.
  • Biggest five-year swings in Revenue: soared 39.48% in 2021 and later increased 1.03% in 2024.
  • Jazz Pharmaceuticals' Revenue stood at $896.7 million in 2021, then grew by 8.41% to $972.1 million in 2022, then grew by 4.1% to $1.0 billion in 2023, then increased by 7.53% to $1.1 billion in 2024, then rose by 10.09% to $1.2 billion in 2025.
  • The last three reported values for Revenue were $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.